Gliclazide 40 mg – Product Overview

Gliclazide 40 mg is a generic oral hypoglycemic agent indicated for the management of type 2 diabetes mellitus. Produced by Panacea Biotech Ltd., each strip contains 10 tablets, and bulk packs are offered in 60, 90, or 120 tablets. This medication belongs to the sulfonylurea class and functions by stimulating insulin secretion from pancreatic beta cells, thereby reducing blood glucose concentrations.

What is Gliclazide 40 mg?

Gliclazide is a synthetic sulfonylurea antidiabetic drug. The 40 mg tablet strength is a standard dose for adults with type 2 diabetes who require additional glycemic control when diet and exercise alone are insufficient. It is marketed as a generic product, providing the same therapeutic benefit as brand‑name sulfonylureas at a lower cost. Pharmacokinetically, Gliclazide is absorbed rapidly, reaches peak plasma concentrations within 2–3 hours, and has a half‑life of approximately 10–12 hours, permitting once‑daily dosing. The drug is extensively metabolized in the liver via cytochrome P450 enzymes, and its inactive metabolites are eliminated primarily through the kidneys.

Uses and Benefits

The primary therapeutic use of Gliclazide 40 mg is to improve glycemic control in patients with type 2 diabetes. Clinical trials have demonstrated that it reduces fasting plasma glucose (FPG) and post‑prandial glucose excursions, resulting in a mean reduction of HbA1c by approximately 0.5–1.0% when used as monotherapy or in combination with other oral antihyperglycemic agents. Improved glucose control is linked to a lower incidence of microvascular complications such as retinopathy, nephropathy, and neuropathy, and may also reduce the risk of macrovascular events when combined with lifestyle modification.

Beyond glucose lowering, Gliclazide is generally weight‑neutral and does not adversely affect lipid profiles. Its once‑daily dosing simplifies the treatment regimen, which can enhance patient adherence. Compared with some other sulfonylureas, Gliclazide exhibits a relatively low propensity to cause severe hypoglycemia when titrated cautiously, making it a suitable option for many patients, including the elderly.

How It Works

Gliclazide binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP‑sensitive potassium channels. This leads to membrane depolarization, calcium influx, and subsequent insulin secretion. Because the drug’s effect is glucose‑dependent, insulin release is modulated by the prevailing glucose concentration, which helps reduce the likelihood of hypoglycemia at therapeutic doses. After oral administration, Gliclazide undergoes hepatic metabolism through CYP2C9 and CYP3A4 enzymes, producing inactive metabolites that are eliminated renally.

Dosage Guidelines

Usual initiation is 40 mg taken once daily with the first main meal of the day, typically breakfast. If glycemic targets are not achieved after 4–6 weeks, the dose may be increased by 20–40 mg at intervals of 1–2 weeks, up to a maximum daily dose of 160 mg. Dose adjustments are recommended for patients with impaired renal function; for example, a daily dose of 20 mg is advised when creatinine clearance falls below 30 mL/min. Elderly patients should start at the lowest dose (20–40 mg) and be monitored closely for hypoglycemia.

When transitioning from another oral hypoglycemic agent, the previous medication should be discontinued before starting Gliclazide to avoid overlapping drug effects. Regular self‑monitoring of blood glucose is essential during dose titration, and patients should be instructed to adjust their diet or activity if they experience recurrent low glucose levels. Dose adjustments may also be required in patients with hepatic impairment or those taking medications that affect the cytochrome P450 system.

Side Effects

Most adverse reactions are mild and include hypoglycemia, dizziness, headache, nausea, and transient skin rash. Rare but serious side effects may involve hepatic enzyme elevation, severe hypoglycemia, or hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to recognize early symptoms of low blood sugar — such as sweating, tremor, confusion, or palpitations — and to treat them promptly with glucose‑containing foods or beverages. If severe hypoglycemia occurs, emergency medical attention is required.

Warnings and Precautions

Gliclazide is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or a known hypersensitivity to the drug. Caution is advised in patients with severe renal or hepatic impairment, as well as in pregnant or breastfeeding women. Concomitant use with certain medications — such as certain antibiotics (e.g., macrolides), antifungals, or beta‑blockers — may potentiate hypoglycemia. Alcohol consumption should be limited, as it can increase the risk of hypoglycemia.

Healthcare providers should monitor liver function tests periodically and assess renal status, especially in patients with comorbidities. Patients with a history of cardiovascular disease should be monitored closely, as hypoglycemia can impose additional cardiac stress. In patients with type 2 diabetes and established cardiovascular disease, careful consideration of cardiovascular safety is recommended.

Storage and Handling

Store Gliclazide tablets at room temperature (15‑30 °C) away from moisture, heat, and direct sunlight. Keep the strip sealed until ready to use to protect tablets from humidity. Do not store in the bathroom or near the kitchen sink. Keep out of reach of children and pets. Dispose of any expired or unused medication according to local regulations.

Drug Interactions

Gliclazide may interact with drugs that affect hepatic metabolism or renal excretion. Concomitant use with certain sulfonamide antibiotics, specific antiviral agents, or non‑steroidal anti‑inflammatory drugs (NSAIDs) can alter its plasma levels. Medications that enhance the hypoglycemic effect — such as high‑dose salicylates, certain antiretrovirals, or beta‑agonists — may increase the risk of low blood sugar. Always review a patient’s complete medication list with a pharmacist or physician before initiating therapy.

Clinical Evidence and Real‑World Outcomes

Randomized controlled studies have consistently shown that Gliclazide reduces HbA1c by approximately 0.5–1.0% when used as monotherapy or as an add‑on to metformin. Real‑world data from observational registries indicate that patients initiated on Gliclazide achieve target fasting glucose levels within 12–16 weeks in a substantial proportion of cases, with a favorable safety profile when dose titration is performed according to guidelines. Post‑marketing surveillance has confirmed a low incidence of serious adverse events, reinforcing the drug’s overall risk‑benefit balance when used appropriately.

Economic analyses suggest that the availability of a generic formulation can improve access to diabetes therapy, particularly in low‑ and middle‑income settings. When compared with other sulfonylureas, Gliclazide demonstrates comparable efficacy but a slightly better tolerability profile, especially regarding the frequency of severe hypoglycemic episodes.

Patient Counseling and Lifestyle Recommendations

Effective diabetes management with Gliclazide requires a comprehensive approach that includes dietary modifications, regular physical activity, and routine self‑monitoring of blood glucose. Patients should be advised to consume meals at regular intervals, avoid skipping meals, and limit intake of high‑glycemic-index foods. Incorporating at least 150 minutes of moderate‑intensity aerobic exercise per week, along with resistance training twice weekly, can enhance insulin sensitivity and improve glycemic outcomes.

Education on recognizing and managing hypoglycemia is essential; patients should carry a source of rapid‑acting carbohydrate (e.g., glucose tablets or sugary drinks) at all times. They should also be instructed to maintain a log of glucose readings and to report any recurrent low episodes to their healthcare provider. Continuous glucose monitoring (CGM) systems may be considered for patients experiencing frequent hypoglycemia or those who desire tighter glycemic control.

Frequently Asked Questions

1. Q: How should Gliclazide 40 mg be stored?
   A: Store at room temperature, away from moisture and heat. Keep the strip sealed until ready to use.
2. Q: Can Gliclazide be taken with other antidiabetic medications?
   A: Yes, it can be combined with metformin or insulin, but dosage adjustments and close glucose monitoring are required to avoid hypoglycemia.
3. Q: Is a prescription required for Gliclazide 40 mg?
   A: A valid prescription from a licensed healthcare provider is required before purchase.
4. Q: Where can I find detailed prescribing information?
   A: Refer to the FDA label or visit FDA Drugs@FDA for comprehensive data.
5. Q: Are there lifestyle recommendations while using Gliclazide?
   A: Yes. A balanced diet, regular physical activity, and routine glucose monitoring enhance treatment effectiveness and reduce the risk of complications.

For additional authoritative information, consult resources such as the MedlinePlus Diabetes Page or the PubMed database, which provide evidence‑based guidance on diabetes management.

Related Products

• Okamet 500 Mg (Metformin)
• Pangraf 0.25 mg (Tacrolimus)
• Pangraf 0.5mg (Tacrolimus)
• Pangraf 1mg (Tacrolimus)
• Pangraf (Tacrolimus)
• Tacrolimus 0.25mg (Generic)
• Pangraf 2mg (Tacrolimus)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)